May 23, 2025: People & Company News
- The acquisition gives Regeneron access to a vast trove of human genetic data, perhaps accelerating drug discovery but also raising concerns about data privacy and security.
- Regeneron Pharmaceuticals will acquire key assets from the bankrupt DNA-testing firm 23andMe for $256 million, according to the Wall Street Journal.
- The acquisition ensures the continuation of 23andMe's consumer testing services.
Regeneron is set to acquire key 23andMe assets in a $256 million deal, a move that includes the Personal Genome Service and vital health-research units. This acquisition raises important questions about genetic data privacy, even as Regeneron vows to maintain existing policies. the transaction, expected to close in Q3 2025, gives Regeneron access to valuable human data. Stay informed on this and more wiht News Directory 3. Discover what’s next for these companies and the future of genetic research.
Regeneron to Acquire 23andMe Assets in $256M deal
Updated May 25, 2025
Regeneron Pharmaceuticals will acquire key assets from the bankrupt DNA-testing firm 23andMe for $256 million, according to the Wall Street Journal. The deal,which is slated to close in the third quarter of 2025,includes 23andMe’s Personal Genome Service,health-research units,and a biobank containing millions of customer genetic samples.
The acquisition ensures the continuation of 23andMe’s consumer testing services. Though, it also sparks concerns about data privacy as Regeneron gains control of a critically important collection of human genetic data.
Regeneron has stated it will adhere to existing 23andMe privacy policies, comply with all applicable laws, and brief a court-appointed ombudsman on its data-security measures.
What’s next
The deal is subject to regulatory approval and customary closing conditions.the integration of 23andMe’s assets into Regeneron’s research and development operations will follow the closing.